multiple myeloma

Conference Coverage

BME Signatures at Baseline and During Treatment Enable Risk Stratifications of Patients With Multiple Myeloma

12/12/2022

In a presentation at the 64th ASH Annual Meeting and Exposition, Simon Steiger, PhD, and colleagues presented a longitudinal study in which they attempted to associate BME samples with multiple myeloma cytogenic and molecular subgroups.

In a presentation at the 64th...

12/12/2022

Journal of Clinical Pathways

Case Report

Acupuncture-exacerbated Pyoderma Gangrenosum Associated With IgG Multiple Myeloma

11/14/2022

Shengxiu Liu ;

Jiajie Lyu ;

Hanshuo Zhang ;

Sun Wang ;

The authors present a case of a 49-year-old female who presented with pyoderma gangrenosum triggered by unregulated acupuncture treatment.

The authors present a case of...

11/14/2022

Wounds

Videos

Taiga Nishihori, MD, Discusses Ixazomib Therapy After AlloHCT for High-Risk MM

06/04/2021

Taiga Nishihori, MD, shares findings from a trial of ixazomib maintenance after alloHCT in patients with high-risk MM. These data were presented at the 2021 ASCO Annual Meeting.

Taiga Nishihori, MD, shares...

06/04/2021

Oncology

Videos

All4Cure: Patient Data Aggregate Platform for Collaborative Multiple Myeloma Care

03/05/2021

Tony Blau, MD, Founder and CEO, provides a demonstration of All4Cure, discusses the vision and need for the platform, and describes its ability to improve patient care.

Tony Blau, MD, Founder and CEO,...

03/05/2021

Journal of Clinical Pathways

Videos

HCRU and Costs Associated With CAR-T Therapy Toxicity Management in MM

12/08/2020

Journal of Clinical Pathways

$Adding Daratumumab to Pomalidomide and Dexamethasone Improves PFS in Relapsed/Refractory MM$

Videos

Adding Daratumumab to Pomalidomide and Dexamethasone Improves PFS in Relapsed/Refractory MM

12/04/2020

Journal of Clinical Pathways

News

Treatment Algorithms for Newly Diagnosed and Relapsed Multiple Myeloma

12/02/2020

Journal of Clinical Pathways

From the Field

Care Coordination Between Prescribers and the Specialty Pharmacy for Multiple Myeloma: Qualitative Insights Into Designing a Quality Improvement Program for Multisite Community Oncology Practices

08/19/2020

Jeffrey F. Patton , MD;

David Blaisdell , BA;

Jonathan K. Kish , PhD, MPH;

Natalie Dickson , MD;

JaLyna Laney , RN, OCN;

Jesus G. Berdeja , MD;

Stacey W. McCullough , PharmD;

Annette Powers , PharmD, MBA;

Ronda Copher , PhD;

Tom Valuck , MD, JD;

Abstract: It is widely recognized that the quality of medical care received in the United States is suboptimal, and poor-quality care may contribute to disparities in cancer incidence and mortality. While...

...

08/19/2020

Journal of Clinical Pathways

Research in Review

Myeloma Treatment Patterns Vary Among European Practices

07/11/2016

JCP Editors

  There is significant variation in how European practices treat patients with multiple myeloma, according to a cross-sectional study published in the British Journal of Haematology. For the study,...

...

07/11/2016

Journal of Clinical Pathways

Daratumumab More Cost Effective for Multiple Myeloma Treatment

06/13/2016

JCP Editors

Daratumumab may be the most cost-effective treatment option for patients with multiple myeloma (MM) compared with other novel therapies, according to a poster presented at the 2016 American Society of Clinical...

...

06/13/2016

Journal of Clinical Pathways